AZ blankets 26,000 pharmacies with Brilinta stocks; Bayer nabs EU approval for long-term contraceptive;

@FiercePharma: Eli Lilly taps India's Strides Arcolab to make/distribute generic cancer drugs in emerging markets. More | Follow @FiercePharma

> Aiming to amp up availability--and sales--of its blood thinner Brilinta, AstraZeneca ($AZN) has rolled out a new program with more than 26,000 pharmacies. Report

> Bayer won European approval for its new long-term contraceptive, a hormone-releasing intrauterine device. Report

> A Canadian court granted class action status to a lawsuit against GlaxoSmithKline ($GSK), which accuses the company of falling short in warning of Paxil's risk of birth defects. Report

> Pfizer ($PFE) launched its targeted lung cancer drug Xalkori in the U.K. for ALK-positive advanced non-small cell lung cancer. Report

> Moody's Investors Service upgraded ratings on Denmark's Novo Nordisk ($NVO) to A1 from A2. Report

> Fitch Ratings affirmed French drugmaker Sanofi ($SNY) at AA- with a stable outlook. Report

> Iran faces widespread drug shortages as banking-industry sanctions affect availability, especially of treatments for cancer, multiple sclerosis and blood disorders. Report

> The BMJ is urging the National Institute for Health and Clinical Excellence to pressure drug companies to produce all data, published and unpublished, from clinical trials. Report

Medical Device News

 @FierceMedDev: SurgiQuest pulled in $18.5M in new funding for an abdominal cavity surgical tool. Release | Follow @FierceMedDev

@MarkHFierce: Another day, another lawsuit against a faulty metal hip replacement--this time against Biomet. Story | Follow @MarkHFierce

 @DamianFierce: The Israeli medical device industry is on the up-and-up, and Medtronic is paying attention, an exec says. News | Follow @DamianFierce

> Device startup nails $3.64M Series A for hemorrhage-control device. Item

> Kona Medical closes $40M round for renal denervation device. News

Biotech News

 @FierceBiotech: In Alzheimer's mystery, key biomarker will determine success of pivotal studies. Story | Follow @FierceBiotech

 @JohnCFierce: At the very least, Merck should redesign the patient selection process on MK-8931 and concentrate on mild/prodomal Alzheimer's cases only. | Follow @JohnCFierce

 @RyanMFierce: AstraZeneca has answered German price cuts to drugs with $AZN workforce cuts of 400-650 workers in the country. Release | Follow @RyanMFierce

> FDA blamed for stymying new antibiotics. Story

> Chelsea Therapeutics sinks on latest PhIII results of lead fainting med. News

> German biotech Wilex slashes staff after Phase III misfire. Report

Drug Delivery News

> Leukemia nanoparticles get drugs to the right spot. News

> Team shoos away superbugs with puffs of powder. Report

> Iluvien stumbles on rocky road to market in U.K. Article

> Dissolving fabric could stop pregnancy, HIV. Story

Biomarkers News

> Experts: Britain's NHS must build genetic testing infrastructure. News

> In Alzheimer's mystery, key biomarker will determine success of pivotal studies. Article

> Supreme Court to tackle gene patent case. Item

> Gene analysis marks new targets against childhood cancer. Report

> Biotech grabs $2M to discover biomarkers for personalized autism treatment. News

> Biomarker spotted for colon cancer stem cells. Story

And Finally... A St. Louis cardiology practice has sued Forest Laboratories ($FRX) for bombarding it with faxed invitations to promotional seminars. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.